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ttp://dx.doi.org/10.1016/j.ajpath.2013.12.019Tumor cells secrete factors that stimulate the migration of peripheral blood leukocytes and enhance
tumor progression by affecting angiogenesis. In these studies, we investigated the effect of morphine, a
known immunosuppressant, on leukocyte migration and recruitment to conditioned media derived from
long-term cultures of mouse Lewis lung carcinoma cells. Our results indicate that morphine treatment
reduced the migration and recruitment of tumor-inﬁltrating leukocytes into Matrigel plugs and polyvinyl
alcohol sponges containing conditioned media derived from long-term cultures of mouse Lewis lung
carcinoma cells when compared with placebo. A reciprocal increase in peripheral blood leukocytes was
observed at the time of plug or sponge removal in morphine-treated mice. Decreased angiogenesis was
observed in conditioned media derived from long-term cultures of mouse Lewis lung carcinoma cells
Matrigel plugs taken from morphine-treated wild-type mice when compared with placebo but was
abolished in morphine-treated m-opioid receptor knockout mice. In addition, in vitro studies using trans-
well and electric cell substrate impedance sensing system studies reveal for the ﬁrst time morphine’s
inhibitory effects on leukocyte migration and their ability to transmigrate across an activated endothelial
monolayer. Taken together, these studies indicate that morphine treatment can potentially decrease
leukocyte transendothelial migration and reduce angiogenesis associated with tumor growth. The use of
morphine for cancer pain management may be beneﬁcial through its effects on angiogenesis.
(Am J Pathol 2014, 184: 1073e1084; http://dx.doi.org/10.1016/j.ajpath.2013.12.019)Supported by research funding from National Institute on Drug Abuse
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Today morphine is still used clinically for chronic pain
associated with cancer growth and treatments with few
alternative options. Understanding the contribution of
morphine to cancer growth is still an important question
because existing reports conﬂict.1,2 Underlying mechanisms
associated with cancer cell initiation and progression to
tumor formation are complex and often patient speciﬁc.
However, one common event is angiogenesis, which is often
driven by inﬂammation and is an important part of tumor
progression, even in tumors of different cellular origins. For
decades scientists have recognized leukocyte contribution to
tumor growth. Both microbial and virus-initiated cancers
have some level of leukocyte inﬁltration, and this is corre-
lated with an increased incidence of tumor formation.3e6stigative Pathology.
.During the early stages of solid tumor growth, poly-
morphonuclear cells, neutrophils, monocytes, macrophages,
dendritic cells, and T lymphocytes inﬁltrate the tumor
microenvironment.7,8 Initially leukocytes eradicate tumor
cells but eventually contribute to blood vessel formation and
maintenance.8 Tumor-derived leukocytes often display an
immunosuppressive phenotype and limit the activation of
effective T-cell tumorekilling responses.9 Chemokines and
Koodie et alproangiogenic factors secreted from hypoxic, stressed, and
dying tumor cells and surrounding stromal cells attract
leukocytes that accumulate within many solid tumor mi-
croenvironments. Once recruited in the hypoxic tumor,
these tumor-promoting leukocytes secrete vascular endo-
thelial growth factor (VEGF), and VEGF secreted from
hypoxic tumor and stromal cells display chemotactic ac-
tivity for monocytes expressing VEGF receptor 1.10
Recruited leukocytes support tumor growth by secreting
additional proangiogenic factors, matrix-remodeling en-
zymes, and chemotactic factors that further sustain leuko-
cyte recruitment and maintain angiogenesis. On stimulation
leukocytes release preformed intracellular granules that
contain VEGF, which further enhance endothelial cell pro-
liferation and tube formation within solid tumors.8 Cyto-
kines, such as tumor necrosis factor (TNF)ea and IL-1,
stimulate the expression of cell adhesion molecules on
tumor-inﬁltrating leukocytes to increase the adhesiveness
between leukocytes and the endothelium for trans-
endothelial migration (TEM).11 Various leukocytes express
integrin b2 (CD18) that combines with numerous other
proteins to form different integrin complexes capable of
engaging with speciﬁc intercellular adhesion molecules
[intercellular adhesion molecule (ICAM) 1, 2, and 3].
ICAMs can be found clustered on activated endothelial cells
exposed to proinﬂammatory stimulus and participate in
leukocyte endothelial transmigration.11 Chronic inﬂamma-
tion leads to increased production of proinﬂammatory me-
diators that further stimulate and enhance inﬂammatory cell
migration and tumor angiogenesis, promoting tumor cell
proliferation and survival, invasion, and metastasis.12
Immune-modulating agents, such as morphine, are well
known to alter leukocyte behavior. These alterations include
effects on monocyte-mediated phagocytosis and activation,
neutrophil and monocyte chemotaxis, macrophage activa-
tion, mitogen-induced proliferation, antimicrobial resistance,
and antibody production.13 Morphine inhibits neutrophil
chemotaxis to serum activated with Escherichia coli, casein,
monocyte inﬂammatory protein 1a, and IL-8.14,15 In a cohort
of opioid treatmentenaive cancer patients, plasma concen-
tration of monocyte inﬂammatory protein 1a signiﬁcantly
decreased during morphine treatment compared with base-
line.16 Studies with mouse, monkey, and carp leukocytes
revealed that morphine impairs leukocyte migration.17e19 In
previous studies, we reported that morphine, through the
m-opioid receptor, inhibited tumor celleinduced angiogen-
esis in mice. We proposed that morphine suppressed
hypoxia-induced tumor cell expression of VEGF, leading to a
signiﬁcantly reduced angiogenesis and tumor cell survival.20
The purpose of this study was to investigate the migration and
recruitment of tumor-inﬁltrating leukocytes after morphine
treatment and their contribution to morphine-mediated inhi-
bition of tumor growth and angiogenesis. Strategies to target
inﬂammatory cells and inhibit inﬂammation-associated
angiogenesis may prove to be effective to reduce tumor
growth and progression.1074Materials and Methods
Animals, Cell Lines, and Reagents
Luciferase (Luc) mice expressing FVB background were
crossed with m-opioid receptor knockout (MORKO) mice
(C57Bl/6  129 Ola background). Male or female C57BL/6
F2 wild-type (WT) mice were used as recipients (bred at the
University of Minnesota speciﬁc pathogen free environment
animal facility). In all experiments, animals were sex and
aged matched (8 to 21 weeks). All experimental protocols
were approved by the University of Minnesota Institutional
Animal Care and Use Committee. Conditioned media (CM)
from spontaneous, mouse-derived Lewis lung carcinoma
(LLC) cells or human ovarian cancer cell line (MA148-CM)
was collected by growing cells in RPMI 1640 medium sup-
plemented with 5% fetal bovine serum (FBS) and 1% Penn-
Strep until conﬂuence. CM was frozen in aliquots for use in
subsequent experiments. Human umbilical vein endothelial
cells (HUVECs; Lonza Group Ltd., Basel, Switzerland) and
human microvascular endothelial cells (huMVECs; derived
from human foreskin) were cultured in endothelial cell
growth media (Lonza). Human PLB985 leukocytes are from
a human myelomonocytic cell line and were cultured in
RPMI 1640 medium supplemented with 5% FBS and 1%
Penn-Strep.
Drug Administration
In all in vivo experiments, mice were administered either 75
mg of slow-release morphine or placebo pellet implanted
s.c. (National Institute on Drug Abuse, National Institutes of
Health) under ketamine and xylazine anesthesia.
LLC Tumor Growth Assay
Tumor growth assay was performed as previously
described.20 Data are from one representative experiment
from two independent experiments (nZ 5 per group). Two
to four sections of individual frozen tumors were acetone
ﬁxed, rehydrated, and blocked in 5% bovine serum albumin
(BSA) at room temperature for 1 hour. Slides were then
washed and stained at 4C overnight with the ﬂuorescently
labeled primary antibodies [ﬂuorescein isothiocyanate
(FITC) for Gr1 and phycoerythrin (PE) for F4/80] in 1%
BSA. Sections were counterstained with DAPI (Sigma, St.
Louis, MO) before image capturing (Nikon, Chiyoda,
Tokyo). Parafﬁn-embedded sections was heated at 65C for
30 minutes, incubated in xylene (10 minutes, 2 times)
followed by ethanol (5 minutes each at 100%, 80%, and
70%), and rehydrated (10 minutes and 5 minutes). A 1
universal retrieval antigen (R&D Systems, Minneapolis,
MN) was applied to slides and heated (15 minutes). Cooled
slides were preincubated at room temperature in 1% horse
serum and 1% BSA (30 minutes at room temperature) and
then primary antibodies (CD31, ICAM-1) resuspended inajp.amjpathol.org - The American Journal of Pathology
Morphine Inhibits Leukocyte Recruitmentincubation buffer (1% horse serum, 1% BSA, and 0.03%
Triton X-100) overnight at 4C.
VEGF- and LLC-CMeInduced Matrigel Plug Assays
Matrigel plug assay was performed as previously described20
with few modiﬁcations using either 1:4 LLC-CM to Matrigel
(n Z 5 mice per group) (BD Biosciences, San Jose, CA) or
100 ng/mL of VEGF admixed in Matrigel (n Z 4 mice per
group). After 7 days, plugs were removed, photographed
before ﬁxation, sectioned, and stained for H&E (Fairview
Riverside Pathology Services, Minneapolis, MN). Hemoglo-
bin levels determined as a measure of angiogenesis using
Drabkin’s reagent (Sigma) (BMG Labtech FLUOstar Plate
Reader, Cary, NC). Plug-inﬁltrated cells were identiﬁed by
ﬂow cytometry and immunohistochemistry using ﬂuo-
rescently labeled antibodies (F4/80, Gr1, Ly6C, Tie2, CD34,
CD45, Ly6G). Peripheral blood was collected through cardiac
puncture and red blood cells lysis. White blood cells were
ﬁxed, stained, and analyzed using ﬂow cytometry (GUAVA
xEasyCyte Cell Analysis Flow Cytometer, Millipore, Bill-
erica, MA). CD31-morphometric analysis for blood vessel
density was performed as described.20
LLC-CMeInduced PVA Sponge Assay for Leukocyte
Migration
Polyvinyl alcohol (PVA) sponge assay was performed as pre-
viously described.23 WT Luc-negative (B6129PF1), positive
(FVB), and MORKO Luc-positive (C57Bl/6Jx129/Ola) mice
were used in these experiments. MORKO Luc-positive mice
were crossed and bred in our laboratory (8 to 20 weeks).
Bioluminescent images were captured after administration of
50 mL of 15 mg/mL of D-luciferin at sponge site using an IVIS
Xenogen whole-body imaging system (University Imaging
Center; University of Minnesota, Minneapolis, MN). Relative
luminescence units of recruited sponge cells (days 1 and 5)
were determined using a luminometer (Turner Designs, Sun-
nyvale, CA). Data are expressed as fold change relative to
placebo-treated mice. The phenotype of PVA sponge-
inﬁltrating cells was determined using ﬂow cytometry. Data
expressed as percentage of positive cells in total events were
analyzed (nZ 2).
Adoptive Transfer Tumor CelleInduced Leukocyte
Migration Assay
WT or MORKO mice were used as hosts or recipients.
Donor bone marrow (BM) was isolated from drug-treated
WT and MORKO Luc-expressing mice. At a ratio of one
donor to two recipients, BM cells were injected into lateral
tail veins 3 hours after pellet and PVA-LLC-CM sponge
implantation. These experiments contained three to ﬁve
mice per group. Eighteen hours after BM injections, the
relative cell recruitment was quantiﬁed using biolumines-
cence (relative luminescence units).The American Journal of Pathology - ajp.amjpathol.orgTEM Using the ECIS System
To further investigate the effects of morphine on leukocyte-
endothelial transmigration, we used the electric cell substrate
impedance sensing (ECIS; Applied Biophysics, Troy, NY)
system that monitors changes in transcellular resistance
(TER). To assess the effect of morphine on the endothelial
compartment, HUVECs were added to 8W10E and ECIS
arrays (gelatin precoated). HUVEC monolayers were
morphine pretreated (1.0 mmol/L for 16 hours) before inter-
action with naive huPLB985 cells and changes in TER
monitored. To assess the effect of morphine on the leukocyte,
huMVEC monolayers were pretreated with TNF-a and
changes in TER monitored on interaction with saline- and
morphine-pretreated huPLB985 cells (1.0 mm overnight).
Cell Migration Using Transwell Assay
To further investigate the effect of morphine on leukocyte
migration in vitro, we used huPLB985 cells and tested che-
motatic migration toward MA148-CM. Approximately,
1  106 cells/mL were pretreated with 1.0 mmol/L saline or
morphine overnight in 5% FBS and RPMI 1640 medium.
The next day, all cells were collected and resuspended in 1
mL of 5% FBS and RPMI 1640 medium and labeled with a 1
mmol/L carboxyﬂuorescein diacetate solution (Invitrogen,
Carlsbad, CA) at 37C for 10 minutes. Labeled cells were
added to the top wells of collagen-coated 3.0-mm pore inserts
(Becton Dickinson, Minneapolis, MN) at 5  105 cells/mL.
Cells were allowed to migrate to bottom wells that contained
5% FBS and RPMI 1640 medium alone or a mix that con-
tained 25% MA148 CM and 5% FBS and RPMI 1640 me-
dium in a 37C, 5% CO2 humidiﬁed incubator. After 6 hours,
cells that had migrated to the bottom wells were collected and
spun down. Supernatants were aspirated and cell pellets were
resuspended in 100 mL of RPMI 1640 medium and placed
into 96-well black ﬂuorescent plates and ﬂuorescence read at
a 560-nm wavelength. Data are expressed as the percent
change from RPMI 1640 medium control. To further eval-
uate the role of morphine on leukocyte migration, human
blood was purchased from the Red Cross (Minneapolis, MN)
and granulocytes separated using Histopaque-1077 as sug-
gested by manufacturers (Sigma-Aldrich, St. Louis, MO).
Cells were counted and incubated for 16 hours with 1.0 mmol/
L saline or morphine before the migration assay as described.
Data are shown as percent change in migration compared
with 5% FBS and RPMI 1640 medium for each treatment.
Data are shown from four different donors.
Cell Adhesion Using the ECIS System
To test the ability of BMcells to attach to ﬁbronectin, 10mg/mL
of ﬁbronectin solution was diluted in water (1:10) to coat
ECIS/8W10E and plates at room temperature for 15 minutes.
Freshly isolated mouse BM cells were pretreated overnight
with 1.0 mmol/L saline or morphine. Approximately 5  1051075
Koodie et alsaline- or morphine -treated mouse BM cells were plated into
each well containing either 5% FBS and RPMI 1640 medium
alone or 50% to 5% FBS and RPMI 1640 medium and 50%
LLC mixture. The arrays were placed in the ECIS instrument
and the resistance values collected under multiple frequency
and time intervals settings for 24 hours. The graph data depict
relative resistance derived from raw resistance values in 5%
FBS and RPMI 1640 medium alone subtracted from 50%
LLC resistance values.
Modiﬁed Under Agar Migration Using the ECIS System
To further assess the effect of morphine on cell migration, we
performed a modiﬁed under agar assay in 8WCP plates as
previously described.21 Brieﬂy, a 0.5% ﬁnal agarose con-
centration solution was made using 1 mL of a 3% agarose
HBSS solution, 5 mL of prewarmed RPMI 1640 medium
supplemented with 10% FBS, 40 mmol/L HEPES, and
0.075% sodium bicarbonate. ECIS/8WCP plates were pre-
treated with 10 mmol/L cysteine and water for 15 minutes at
room temperature. Approximately 250 mL of the 0.5%
agarose solution was added and allowed to solidify slowly at
room temperature. Once solidiﬁed, gel was placed at 4C for
15 minutes, and a 2-mm biopsy punch was used to make
wells on each side, equidistant from the electrode. Agarose
plugs were removed through low aspiration using a Pasteur
pipette attached to a vacuum line. Approximately 15 mL
containing 1 106 mouse BM cells pretreated overnight with
1.0 mmol/L saline or morphine was added to wells opposite
that containing 5% FBS and RPMI 1640 medium or LLC-
CM. The array was placed in the ECIS instrument and the
resistance values collected under multiple frequency and time
intervals settings. The graph data depict the relative resis-
tance derived from raw resistance values collected (and after
export into Microsoft Excel for analysis). Relative resistance
values were derived by subtracting actual resistance recorded
values at each time point for saline-treated BM cell migration
(basal migration) toward 5% FBS and RPMI 1640 medium
from saline-treated BM cell migration toward LLC-CM.
Similarly, relative resistance values for morphine-treated
BM cells were derived from subtracting 5% FBS and
RPMI 1640 medium actual resistance recorded values from
morphine-treated BM cell migration toward LLC-CM.
Adhesion Molecule Expression
To assess whether morphine altered the expression of
adhesion molecules involved in transmigration, we treated
naive huPLB985 cells with 1.0 mmol/L saline or morphine
overnight. Pretreated cells were then incubated with 50 to
100 ng/mL of TNF-a and MA148-CM for 15 minutes to 24
hours. Cells were then ﬁxed at various time points and
stained with anti-human CD18 (b2) antibodies. HUVECs
were grown in monolayers and then pretreated with 1.0
mmol/L saline or morphine overnight. Pretreated HUVECs
were then treated with TNF-a or E. coliederived1076lipopolysaccharide (LPS) for 4 hours. Cells were scraped
and immediately ﬁxed and then subsequently stained for
vascular endothelial cadherin and ICAM-1. Antibody-
stained cells were then r-suspended in PBS and azide and
analyzed using a BD FACS Canto Flow Cytometer (Becton
Dickinson). Data are expressed as a percentage of a ﬁxed
number of gated cells.
Statistical Analysis
Differences in mean values between the two groups were
analyzed using the two-tailed Student’s t-test. P < 0.05 was
considered statistically signiﬁcant.
Results
Morphine Reduces Leukocyte Migration in an LLC Solid
Tumor Model
To study the effects of long-term morphine administration on
tumor growth and angiogenesis, LLC cells were injected s.c.
into placebo- or morphine-treated athymic mice. Tumor
volume was recorded as a measure of tumor progression and
tumor mass removed after 21 days of s.c. implantation.
During the 21-day period, mice received supplemental doses
of saline or morphine i.p. to prevent withdrawal and maintain
morphine at analgesic levels. Morphine treatment decreased
tumor growth progression when compared with placebo
(Figure 1A, P < 0.05). Representative H&E-stained tumor
sections taken from different placebo-treated mice
(Figure 1B) showed successful tumor growth as indicated by
an increased cell density, unlike tumors taken from
morphine-treated mice (Figure 1C). Tumor sections were
further quantiﬁed for angiogenesis using anti-CD31 (red)
counterstained with nuclear DAPI stain (blue). As shown in
Figure 1D, sections taken from individual placebo-treated
mice showed more intense CD31 staining and developed
vascular network compared with sections analyzed from
morphine-treated mice (Figure 1E). Morphometric analysis
using reindeer plug-in functions for Adobe PhotoShop
(Adobe Systems Inc., San Jose, CA) conﬁrmed that morphine
treatment reduced the overall number of vessels formed
within the solid tumors (vessel density), the average vessel
length, and branching points (Figure 1F). To assess leukocyte
inﬁltration, frozen tumor sections were grossly examined for
the presence of leukocytes using ﬂuorescently labeled anti-
bodies against Gr1þ neutrophils (green) and F4/80þ macro-
phages (red). Figure 1, G, H, J, and K, shows ﬂuorescent
captured images showing DAPI nucleus (blue) merged with
corresponding Gr1þ neutrophils (green) and F4/80þ macro-
phages (red), respectively. Gr1þ neutrophil and F4/80þ
macrophage clusters were easily detected within tumor sec-
tions taken from placebo-treated mice (Figure 1, G and J). In
contrast, sections from morphine-treated mice (Figure 1, H
and K) displayed a marked reduction in Gr1þ neutrophil
(Figure 1I; P < 0.011) and F4/80þ macrophage (Figure 1L;ajp.amjpathol.org - The American Journal of Pathology
Figure 1 Effect of morphine on leukocyte inﬁltration into a solid tumor microenvironment. A: Graph shows morphine decreased tumor growth when
compared with placebo treatment (nZ 5 per group) observed during 21 days. H&E-stained LLC tumor sections taken from two distinct placebo-treated (B) and
morphine-treated (C) mice on day 21. Fluorescent images show frozen tumor sections stained for CD31-positive endothelial cells (red) counterstained with
DAPI [nuclear stain (blue)] from placebo-treated (D) and morphine-treated (E) mice. F: Morphometric analysis showing relative blood vessel density, length,
and branching was determined using reindeer plug-in functions for Adobe Photoshop. The inﬁltration of Gr1þ neutrophils (green) from placebo-treated (G)
and morphine-treated (H) mice are shown, as well as F4/80þ macrophages (red) from placebo (J) and morphine (K) merged with corresponding DAPI.
Corresponding relative ﬂuorescent units (RFU) between groups are shown (I) and (L). *P < 0.05, **P < 0.01 (A); P < 0.011 (I); P < 0.025 (L). Scale barZ
100 mm (B and C). Original magniﬁcation 4 (B and C); 20 (D and E); 10 (G, H, J, and K).
Morphine Inhibits Leukocyte RecruitmentP < 0.025) inﬁltration, respectively. To further assess
whether increased leukocyte inﬁltration coincided with
increased angiogenesis, tumor sections were double stained
for the presence of Gr1þ leukocytes and CD31þ endothelial
cells. As shown in Supplemental Figure S1A, tumor sections
from placebo-treated mice showed intense CD31 bloodThe American Journal of Pathology - ajp.amjpathol.orgvessel (red) staining in close approximation to Gr1þ leuko-
cyte clusters. In contrast, morphine tumor sections had
reduced angiogenesis with fewer and smaller Gr1þ leukocyte
clusters (Supplemental Figure S1B). These results suggest
that morphine suppressed leukocyte inﬁltration, which may
have contributed to the decrease in tumor growth.1077
Figure 2 A: Effect of morphine on leukocyte inﬁltration. LLC cells secrete chemotactic factors as determined using an ELISA. LLC-CMeinduced leukocyte
inﬁltration as seen in H&E-stained Matrigel plugs (inset) taken from placebo- and morphine-treated mice (B) (nZ 5 per group); leukocyte accumulation near
blood vessels (arrows) at the plug periphery (C) and cell nuclei using DAPI stain on sections showing plug centers (D). E: Graph shows relative hemoglobin
levels of Matrigel plugs removed on day 7 and determined using a standard curve from WT and MORKO mice (nZ 4 per group) implanted with either placebo or
morphine. F: Fluorescent captured images of CD31-PEestained (red) Matrigel plug (containing 100 ng/mL of VEGF) sections taken from WT and MORKO placebo
and morphine pellet implanted mice. G: Quantiﬁcation of blood vessel density using morphometric analysis. *P < 0.05; ***P < 0.005. Scale bars: 100 mm (B);
20 mm (C and D). Original magniﬁcation 4 (B); 20 (C and D).
Koodie et alMorphine Reduces Angiogenesis Induced by LLC-CM
To study the effect of leukocyte inﬁltrationon angiogenesis,we
next performed amodiﬁedMatrigel plug angiogenesis assay in
immune competent mice. Because hypoxic tumor cells secrete
numerous chemotactic factors that can attract leukocytes into
the tumor sites, we screened LLC cells for monocyte inﬂam-
matory protein 2, keratinocyte chemoattractant, and monocyte
inﬂammatory protein 1 in cell culture supernatants. Indeed,
ELISA conﬁrmed that LLC cells secrete these proteins
(Figure 2A).We therefore admixedLLC-CMintoMatrigel and
injected equal volumes s.c. in placebo- and morphine-
pretreated WT mice. Analysis of H&E-stained plug sections
from placebo-treated mice showed massive inﬁltration of leu-
kocytes in response to tumor-derived chemokines (Figure 2B),1078suggesting that CM alone was sufﬁcient to recruit host cells. In
contrast to placebo, morphine treatment reduced host cell
recruitment from blood vessels surrounding theMatrigel plugs
(Figure 2C) and leukocyte inﬁltration into plug centers
(Figure 2D). In subsequent experiments, hemoglobin levels
were determined as a measure of angiogenesis, and morphine
administration signiﬁcantly decreased LLC-CMeinduced
angiogenesis (Figure 2E; P < 0.005) in vivo. To assess the
involvement of m-opioid receptors in morphine-induced inhi-
bition of angiogenesis, similar experiments were performed in
MORKOmice. Placebo- and morphine-treatedMORKOmice
had similar levels of LLC-CMeinduced angiogenesis
(Figure 2E). Because LLC-CMeinduced angiogenesis was
abolished in morphine-treated MORKO mice, this effect is
likely mediated through a classical opioid receptor.ajp.amjpathol.org - The American Journal of Pathology
Figure 3 Effect of morphine on leukocyte migration toward tumor-derived factors using a PVA sponge assay. A:Whole-body bioluminescent captured images
showing inﬁltration of Luc-expressing BM cells (injected i.p.) into PVA-LLC-CMecontaining sponges (arrow) from placebo (top row) and morphine pelleted mice
(bottom row), nZ 4 per group).B:Graph shows the percentage of total inﬁltrating leukocytes into PVA-LLC-CM sponges after 24 hours of implantation in placebo-
andmorphine-treatedmice. Graphs show the relative percentages of Gr1þ neutrophils (C) and Ly6Cþmonocytes (D) on day 1 and day 5 (E and F) from placebo- and
morphine-treated mice (nZ 5 per group). G: Graph shows the relative percentage of leukocytes that inﬁltrated LLC-CM Matrigel plugs (inset). H: The corre-
sponding peripheral blood levels at the time of plug removal as determined using ﬂow cytometry (nZ 5 per group). *P < 0.05, **P < 0.01, ***P < 0.001.
Morphine Inhibits Leukocyte RecruitmentMorphine-Reduces VEGF Induced Angiogenesis
To further assess immune cell contribution to angiogenesis,
we tested the effect of morphine on VEGF-induced angio-
genesis using a modiﬁed Matrigel plug assay in immune
competent mice. Matrigel admixed with recombinant VEGF
(100 ng/mL) was injected s.c. in WT and MORKO drug
pretreated mice (7 days). VEGF-plug sections from placebo-
WT mice stained with anti-CD31 (red) revealed successful
angiogenesis (Figure 2F). These studies also found that
when compared with placebo morphine treatment decreased
vessel formation within VEGF Matrigel plugs from WT
mice (P < 0.0012; Figure 2G). Unlike WT mice, morphine
treatment of MORKO mice did not affect overall vessel
density because levels were comparable to placebo-treated
WT mice (Figure 2, F and G). H&E-stained VEGF-plug
sections from morphine-treated WT mice had reduced
leukocyte inﬁltration (Supplemental Figure S2C) whenThe American Journal of Pathology - ajp.amjpathol.orgcompared with placebo (Supplemental Figure S2A). Inﬁl-
trated cells were identiﬁed as monocyte-macrophages [F4/
80 (red) and MAC3 (green)] and endothelial cells [CD31
(red)] (Supplemental Figure S2, B, D, and EeH). These
results suggest that morphine disrupts VEGF-induced
angiogenesis of inﬁltrating leukocytes to reduce tumor
growth in mice.Morphine Reduces LLC-CMeInduced Leukocyte
Migration in a PVA Sponge Assay in Mice
To investigate the effect of morphine on leukocyte migra-
tion, we ﬁrst compared the recruitment of BM-derived
myeloid cells expressing LucþBM into inert PVA sponges
and characterized the recruited cells.
PVA sponges were presoaked with LLC-CM and
implanted s.c. inWTmice preimplanted with either a placebo1079
Figure 4 Effect of morphine on leukocyte migration into LCC-derived conditioned mediaecontaining PVA sponge assay in mice. A: Graphs show the fold
change in RLU. Luminescence was collected as a measure of LucþBM inﬁltrating preimplanted LLC-CM-PVA sponges in WT and MORKO Luc-expressing mice
(n Z 4 per group) (*P < 0.25). Graphs show the relative migration of WT LucþBM cells isolated from placebo- and morphine-treated Luc-positive mice and
injected via tail vein into non-Luc MORKO host mice (nZ 4 per group) (*P < 0.05) (B); the relative migration of naive MORKO LucþBM cells in drug pretreated
WT mice (nZ 6 per group) (*P < 0.005) (C); percent change in normalized TER from time on addition of naive human PLB985 cells to vehicle and morphine
(1.0 mmol/L) pretreated HUVECs (D); and saline- or morphine-pretreated huPLB985 cells to human TNF-a (100 ng/mL every 2 hours)epretreated huMVECs (E).
LPS induces increase in ICAM-1 on HUVECs as determined using ﬂow cytometry (*P < 0.05) (F).
Koodie et alor morphine pellet. BM-Lucþ cells were injected i.p., and 24
hours later, mice were imaged after injection of luciferin
substrate directly at the sponge site. Captured whole-body
bioluminescent images showed successful recruitment of
LucþBM cells into LLC-CM PVA sponges from placebo-
treated mice (Figure 3A); however, morphine-pretreated
mice showed reduce bioluminescent signals (Figure 3A).
Flow cytometry analysis of recruited cells, shown on day 1,
recruited sponge cells consisted primarily of BM myeloide
derived cells (CD45þ), undifferentiated progenitors or stem
cells (CD34þ), neutrophils (Gr1þ), monocytes (Ly6Cþ), and
macrophages (F4/80þ). Sponges taken from morphine-
treated mice had a signiﬁcantly lower recruitment of
CD45þ (P < 0.001), CD34þ (P < 0.03), Gr1þ (P < 0.017),
Ly6Cþ (P < 0.002), and F4/80þ (P < 0.001) LucþBM cells
(Figure 3B). These results clearly demonstrate that morphine
decreased leukocyte migration and recruitment into the tumor
microenvironment.
To rule out the possibility that morphine was preventing
leukocyte release from BM, we assessed leukocyte levels
in peripheral blood collected at the time of LLC-CM
sponge removal. As expected, there was reduced inﬁltra-
tion of Gr1þ neutrophils and granulocytes into sponges
from morphine-treated mice (approximately 2.3%) when1080compared with placebo (approximately 5.7%) on day 1
(n Z 4, P < 0.015, Figure 3C); however, there was a
reciprocal increase in Gr1þ cells in peripheral blood from
morphine-treated mice (approximately 18.4%). Our results
also show levels of Gr1þ cells in peripheral blood was
signiﬁcantly greater after morphine when compared with
placebo treatment (approximately 3.0%) (nZ 4, P < 0.01,
Figure 3D). By day 5 PVA sponges from placebo- and
morphine-treated mice had similar levels of Gr1þ cells
(P Z 0.396, Figure 3E). However, peripheral blood Gr1þ
cells was still signiﬁcantly higher with morphine treatment
when compared with placebo (PZ 0.005, Figure 3F). LLC-
CM recruited sponge cells had a granulocytic phenotype
and expressed additional leukocyte markersdLy6G [FITC
(green)] and CXCR2 [PE (red)] (Supplemental Figure S2,
IeK). Analysis of Ly6Cþ monocytes revealed similar
trends as samples from morphine-treated mice: reduced
Ly6Cþcell recruitment into LLC-CM sponges when
compared with placebo on experimental day 1 and day 5
(Figure 3, D and F). On day 1, peripheral blood Ly6Cþ
monocyte levels revealed no difference with morphine
treatment; however, on day 5 peripheral blood levels of
Ly6Cþ cells were signiﬁcantly higher in morphine- than
placebo-treated mice (PZ 0.005, Figure 3F).ajp.amjpathol.org - The American Journal of Pathology
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LLC-CM in Matrigel and injecting s.c. in drug-pretreated
mice (7 days, Figure 3G). Relative to placebo, Matrigel plugs
removed from morphine-treated mice had lower inﬁltrating
neutrophils (Gr1þ, approximately 35%), monocytes (Ly6Cþ,
approximately 30%), and endothelial progenitors (Tie2þ,
approximately 40%) and signiﬁcant reduction in macro-
phages (F480þ, approximately 15%, PZ 0.025, Figure 3G).
Analysis of peripheral blood collected at the time of plug
removal also revealed signiﬁcantly greater circulating neu-
trophils (Gr1þ, P Z 0.0000001), monocytes (Ly6Cþ,
P Z 0.0000004), macrophages (F4/80þ, P Z 0.002), and
endothelial progenitors (Tie2þ, PZ 0.0005) with morphine-
compared with placebo-treated mice (nZ 5; Figure 3H). The
observed reduction inMatrigel plug leukocyte inﬁltration and
reciprocal increase in peripheral blood levels in the presence
of morphine suggest that morphine reduced leukocyte
recruitment through defects in leukocyte transmigration.
Morphine Alters Leukocyte Transmigration in Vivo and
in Vitro
To further investigate the effect of morphine on leukocyte
migration and the involvement of the m-opioid receptors in
morphine inhibition of leukocyte recruitment, we performed
a LLC-CM sponge assay in WT and MORKO Luc-
expressing mice (1 day). Morphine treatment reduced the
recruitment of LucþBM cells in WT mice when compared
with placebo (P < 0.025) but had no signiﬁcant effects in
MORKO Lucþ mice (n Z 4, Figure 4A).
To test the possibility that morphine acted directly on
the leukocytes to reduce trafﬁcking into LLC-CM PVA
sponges, placebo or morphine-pretreated WT LucþBM cells
were injected via tail vein into drug-pretreated MORKO
recipients preimplanted with LLC-CM sponges. Our results
indicate that morphine-pretreated WT LucþBM donor cells,
although not statistically signiﬁcant, migrated to a lesser
extent than placebo-treated WT LucþBM donor cells in
placebo-treated MORKO host mice (13.63%); this was
further reduced when MORKO host mice were pretreated
with morphine (41.4%, Figure 4B).
To evaluate the effect of morphine solely on the ability of
the host endothelium to allow leukocyte transmigration, the
inﬁltration of donor-derived MORKO LucþBM cells into
LLC-CM PVA sponges was compared in placebo and
morphine-pretreated WT non-Luc recipient mice. Our re-
sults indicate that morphine signiﬁcantly reduced the
migration of MORKO BM-Lucþ donor cells in WT mice by
75% when compared with placebo treatment (P < 0.005,
Figure 4C). Taken together, these results suggest that mor-
phine’s inhibition of leukocyte recruitment involves a
classic opioid receptor and occurs as a result of its effects on
the host endothelium.
To further evaluate the effect of morphine on TEM, we
used the ECIS system that monitors changes in TER or TER
in real time in vitro. HUVECs were grown on gelatinThe American Journal of Pathology - ajp.amjpathol.orgprecoated ECIS arrays. As the HUVECs attached, the TER
increased and plateaued at maximum spreading when cell-
cell contact was achieved. At this point, naive huPLB985
cells, a monocytic granulocytic cell line, were added to
vehicle or morphine-pretreated HUVECs. Compared with
HUVEC-only wells, the addition of naive huPLB985 cells
to saline-pretreated HUVECS resulted in a notable loss
in TER, which was indicative of successful leukocyte-
endothelial interaction in preparation for TEM. Unlike
saline-pretreated HUVECs, 100 nmol/L to 1.0 mmol/L
morphine pretreatment resulted in a notable increase in TER
on addition of huPLB985 cells (Figure 4D).
To test the effect of morphine solely on the huPLB985
cells’ ability to undergo TEM, huMVEC monolayers (at
maximum TER) were ﬁrst activated with 100 ng/mL of
human TNF-a for 2 hours to mimic an inﬂammatory state.
Saline- and morphine-pretreated huPLB985 cells were then
added and the TER monitored over time. Saline-pretreated
huPLB985 cells interacted successfully with the huMVEC
monolayers to produce a notable decrease in TER (Figure 4E).
Unlike saline, initially morphine-treated huPLB985s were
unable to transmigrate as indicated by the increased TER
generated by huMVECs during the initial interaction.
Morphine-pretreated huPLB985 cells eventually trans-
migrated, but the loss in TER generated was not to the extent
of that seen with saline-pretreated huPLB985 cells. These
results support our in vivo observations and suggest that
morphine can exert independent effects on leukocytes and
endothelial cells to result in a net reduction in leukocyte TEM.
To further investigate the effects of morphine on trans-
migration, we assessed the expression of known leukocyte
and endothelial cell adhesion molecules involved in leuko-
cyte endothelial transmigration. To do this, HUVEC
monolayers were pretreated with 1.0 mmol/L morphine for
18 hours before 100 ng/mL of LPS treatment (2 hours).
HUVECs were analyzed for ICAM-1 and vascular endo-
thelial cadherin expression using ﬂow cytometry. LPS
treatment of HUVECS in vitro increased ICAM-1 expres-
sion; however, this was reduced in the presence of morphine
(Figure 4F). Additional examination of day 21 tumor sec-
tions revealed abundant ICAM-1 expression within CD31þ
blood vessels at the tumor periphery. As shown previously,
morphine treatment reduced CD31 staining, and ICAM-1
was weakly present in blood vessels at the tumor periph-
ery (Supplemental Figure S2L). In addition, LPS and TNF-a
treatment decreased vascular endothelial cadherin levels
when compared with untreated controls (P Z 0.0505 for
LPS and P Z 0.025 for TNF-a). In contrast, morphine
pretreatment prevented the LPS and TNF- a reduction in
vascular endothelial cadherin in HUVECS cultured in vitro
(Supplemental Figure S3A, P  0.05). To assess cell
adhesion molecules on leukocytes, saline- and morphine-
pretreated huPLB985 cells were treated with 50 to 100 ng/
mL of TNF-a for 24 to 48 hours. At 48 hours, 100 ng/mL of
TNF-a was sufﬁcient to increase the total percentage of cells
expressing CD18 by 20.34% (P Z 0.007). Interestingly,1081
Koodie et almorphine pretreatment prevented the TNF-aeinduced in-
crease in CD18 expression (Supplemental Figure S3B,
PZ 0.0009). To further assess leukocyte inﬁltration, tumor
sections were stained for CD18þ BM-derived myeloid cells
using monoclonal antibodies against CD45-PE (red) and
CD18-FITC (green) on frozen tumor sections from different
experimental mice. CD45þ/CD18þ double positive cells
were easily identiﬁable in sections from individual mice
treated with placebo (Supplemental Figure S3C). Unlike
placebo, morphine treatment reduced the accumulation of
CD45þ/CD18þ leukocytes within the tumor microenviron-
ment. These results suggest that morphine can potentially
alter the expression of cell adhesion molecules, reducing the
ability to slow or adhere ﬁrmly before TEM and thus reduce
extravasation into the tumor site.
To further investigate the mechanisms associated with
morphine’s inhibition of leukocyte migration into the tumor
microenvironment in vivo, we performed a series of in vitro
chemotaxis and cell adhesion assays. Our results indicate that
morphine treatment blunted the chemotactic migration of
huPLB985 cells toward CM derived from a human ovarian
cancer cell line, MA-148 (Supplemental Figure S4A).
Experiments assessing the migration of human-derived
peripheral blood granulocytes toward MA-148 CM revealed
that in 3 of 4 donors morphine signiﬁcantly reduced chemo-
taxis when compared with saline treatment (Supplemental
Figure S4B, P < 0.05). To determine whether morphine
altered leukocyte adhesion, we investigated the effect of
morphine on the LLC-CMeinduced adhesion of mouse BM
cells to ﬁbronectin (FN) in vitro. Our results indicate that
morphine reduced LLC-CMeinduced ability to adhere to
FN in vitro when compared with saline (Supplemental
Figure S4C, P < 0.05). Using The ECIS system, we per-
formed a modiﬁed under agar assay to assess chemotactic
migration that is dependent on adhesion to matrix substrates.
In this assay, we found that saline-treated mouse BM cells
were capable of migrating toward LLC-CM as indicated by
the increased resistance generated as the cells adhered and
migrated across the electrodes. In contrast, morphine-treated
cells migrated, to a lesser extent, because resistance gener-
ated was lower than that of saline-treated cells (Supplemental
Figure S4D). The data from these in vitro studies suggest that
morphine decreased chemotactic migration and leukocyte
adhesion to alter transmigration, further supporting our in vivo
observations.Figure 5 A: Schematic shows the working model for the effect of
morphine on leukocyte migration. Morphine suppresses leukocyte inﬁltra-
tion to reduce angiogenesis associated with tumor growth. Leukocytes
normally circulate freely in peripheral blood. B: Once an infection or injury
occurs, damaged and stressed cells secrete a host of cytokines and che-
mokines that alter cell motility and promote slow rolling of activated
leukocytes for ﬁrm binding, adhesion, and transmigration through the
receptive endothelium. Data suggest that morphine alters leukocyte and
endothelial cell expression of cell adhesion molecules necessary for effec-
tive TEM, leading to either slowed and/or delayed inﬁltration into the
tumor tissue.Discussion
Angiogenesis, the formation of new blood vessels within the
growing tumor, occurs through the cooperative efforts of
tumor- and myeloid-derived BM cells.8 In previous studies,
we demonstrated that hypoxia-induced tumor cell expression
of VEGF is altered in the presence of morphine treatment,
resulting in decreased angiogenesis, tumor cell proliferation,
and growth.20 Morphine, a known immunosuppressant, has1082profound effects on immune cell trafﬁcking, cytokine pro-
duction, and functionality.13 In this study, we found that in
a s.c. LCC tumor model, long-term morphine administration
reduced tumor growth and immune cell inﬁltration
(Gr1þ neutrophils and F4/80þ macrophages). In addition,
morphine-suppressed tumor cell CM induced host leukocyte
recruitment and angiogenesis in WT but not MORKO mice.
Because morphine’s inhibition of leukocyte recruitment was
not observed inMORKOmice, this suggests that this effect is
likely mediated through classic opioid receptors.
Tumor cells secrete a host of factors, many of which
attract immunosuppressive, BM-derived macrophage cells
that contribute to angiogenesis within the developing tumor
microenvironment. We report for the ﬁrst time that long-
term morphine administration disrupted the chemotactic
migration of BM-derived macrophage cells with known
roles in tumor progression and angiogenesis. These results
are in agreement with previous studies assessing the effect
of morphine on leukocyte migration in carp, mice, and
monkeys.17e19 Studies analyzing the effect of morphine on
BM-derived tumor-inﬁltrating leukocytes are scarce. Weajp.amjpathol.org - The American Journal of Pathology
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derived progenitors, granulocytes, monocytes, and macro-
phages. We also identiﬁed a subset of Tie-2 monocytes, an
endothelial cell precursor shown to integrate into developing
vasculature within the tumors.8 In support of these obser-
vations, Lam et al22 reported in an in vivo excisional wound
model that long-term morphine administration reduced
endothelial progenitors (identiﬁed as CD34þ/CD133þ) in
circulation, leading to impaired angiogenesis in mice. Our
results are consistent with their ﬁndings that morphine can
also impair the mobilization of endothelial progenitors to
suppress angiogenesis within a tumor microenvironment
and an excisional wound model.20,23 Furthermore, adoptive
transfer experiments examining donor WT leukocyte
recruitment in MORKO host mice and donor MORKO
leukocyte recruitment in WT host mice suggest that
morphine exerts independent inhibitory effects on both the
circulating leukocytes and host vascular endothelium to
reduce leukocyte recruitment. In an attempt to understand
why morphine decreased LLC-CMeinduced BM cell
recruitment in vivo, we assessed peripheral blood to rule out
the possibility that morphine was preventing leukocyte
release. Our results indicate that morphine treatment
signiﬁcantly suppressed leukocyte inﬁltration into the PVA
sponges with a reciprocal increase in circulating leukocytes.
These results suggested that the morphine-induced inhibi-
tion in leukocyte recruitment was a result of defects in
transmigration and not due to defects in BM leukocyte
release. Studies in mice show that inhibiting or depleting
neutrophils reduces overall solid tumor growth and metas-
tasis.24 Neutrophils secrete proangiogenic factors stored
within granules.25,26 Experiments inhibiting neutrophil
elastase resulted in reduced VEGF and platelet-derived
growth factor release to inhibit tumor cell proliferation
and cell invasion.27 The angiogenic response induced by IL-
8 was found to be neutrophil dependent and was reversed on
neutrophil depletion.28 Once recruited to the tumor site,
polymorphonuclear leukocytes release chemoattractants that
recruit more proinﬂammatory leukocytes.29 The continued
recruitment of leukocytes generates a nonhealing wound.
The possibility that morphine inhibited the initial neutrophil
recruitment and therefore dampened the further recruitment
of proinﬂammatory cytokines is plausible; however, more
studies are necessary.
Morphine decreases the tight junction protein zonula
occludens protein 1 expression in human brainederived
microvascular endothelial cells, and this may be one mecha-
nism by which morphine alters vascular permeability.30 It is
important for us to distinguish between passive and active
migration of cells out of circulation and into tissues (extrav-
asation). Leukocyte extravasation is awell-studied and tightly
orchestrated process that involves leukocyte rolling, adhe-
sion, tight binding, and transmigration in response to che-
mokine secretion, integrin and selectin activation, and
interaction producing cytoplasmic changes for cell migration.
Because morphine inhibits tight junction protein expressionThe American Journal of Pathology - ajp.amjpathol.orginducing permeability changes, one might predict that
morphine should allow greater leukocyte inﬁltration. How-
ever, in our model we see a reduction in leukocyte extrava-
sation, suggesting that morphine-induced changes in vascular
permeability and leukocyte extravasation differ considerably
and may operate independently. Morphine reduces embry-
onic kidney cell and tumor cell adhesion to extracellular
matrix substrates.31,32 To investigate the mechanisms
involved in morphine’s inhibition of leukocyte trafﬁcking
from peripheral blood circulation into the tumor microenvi-
ronment in vivo, we performed a series of in vitro chemotaxis
and cell adhesion assays. Morphine treatment blunted
the migration and altered leukocyte adhesion and TEM,
supporting our in vivo observations. Serum from human
patients with myocardial infarction has high ICAM-1 and
L-selectin levels that are reduced with morphine treatment.32
Similarly, other independent investigations have found an
inhibitory effect of morphine on inﬂammation-induced
ICAM-1, vascular cell adhesion molecule 1, and E-selectin
using HUVECs as an in vitro model.33e35 To get a better
understanding of the cellular mechanisms bywhichmorphine
altered leukocyte transmigration, we also assessed the effect
of morphine on the expression of known leukocyte and
endothelial cell adhesion molecules, critical for successful
transmigration in vivo. Morphine alters the LPS (derived from
E. coli)einduced up-regulation of ICAM-1 in HUVECs.
Results from our experiments are consistent with previous
studies because morphine pretreatment altered the expression
of CD18 (b subunit; pairs with CD11a and known as
lymphocyte functioneassociated antigen 1; interacts with
ICAM-1 clusters found on endothelial cells) using the
huPLB985 granulocyte-monocyte cells exposed to inﬂam-
matory signals (LPS or TNF-a). These ﬁndings suggest
that morphine can alter leukocyte TEM into the tumor
microenvironment by altering cell adhesion molecule
expression on both the leukocyte and endothelial cells.
Further studies are necessary to determine the extent of this
inhibition and intracellular signaling associated with these
defects.
In summary, our studies indicate for the ﬁrst time that
long-term morphine treatment reduces leukocyte migration
and recruitment to reduce angiogenesis and tumor growth
(Figure 5). Strategies to target inﬂammatory cells, and inhibit
inﬂammation-associated angiogenesis to potentially reduce
neovascularization, associated with increasing tumor growth
and progression, are highly desirable. Morphine adminis-
tered for cancer pain management in humans may not be as
detrimental but useful in the disease treatment itself.Acknowledgments
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